An AllTrials project

NCT02296112: A reported trial by Vanderbilt-Ingram Cancer Center

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT02296112
Title A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations
Results Status Reported
ACT or pACT? This is what FDAAA officially calls a "probable Applicable Clinical Trial"
Start date Jan. 31, 2015
Completion date Aug. 31, 2018
Required reporting date Aug. 31, 2019, midnight
Actual reporting date July 15, 2019
Date last checked at ClinicalTrials.gov Aug. 26, 2025
Days late None